{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:13Z","timestamp":1792788073961,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dalian Science and Technology Talent Innovation Support Program","award":["2024RY003"],"award-info":[{"award-number":["2024RY003"]}]},{"name":"Young Top Talents in the Xingliao Talents Program of Liaoning Province","award":["XLYC2403127"],"award-info":[{"award-number":["XLYC2403127"]}]},{"name":"Shanghai Municipal Central Government Funds for Guiding Local Scientific and Technological Development","award":["YDZX20213100001002"],"award-info":[{"award-number":["YDZX20213100001002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82271524"],"award-info":[{"award-number":["82271524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) is the second most prevalent neurodegenerative disorder worldwide. The pathogenesis of PD is driven by multifactorial mechanisms involving a complex interplay among environmental exposures, genetic susceptibility, and aging-related processes. Among genetic contributors, heterozygous pathogenic variants in the\n                    <jats:italic>GBA1<\/jats:italic>\n                    gene represent the most significant heritable risk factor for PD. The disease mechanisms of\n                    <jats:italic>GBA1<\/jats:italic>\n                    defects in PD remains incompletely understood. It has been proposed that a partial loss-of-function of the lysosomal enzyme glucocerebrosidase, or potential toxic gain-of-function effects (e.g., endoplasmic reticulum stress) might contribute to the disease. These processes initiate a cascade of pathophysiological events, including dysregulated sphingolipid metabolism, compromised lysosomal-autophagic function, mitochondrial dysfunction, and accelerated \u03b1-synuclein aggregation. Subsequent dopaminergic neurodegeneration and sustained neuroinflammatory cascades ultimately drive PD progression. Nevertheless, the precise molecular mechanisms linking\n                    <jats:italic>GBA1<\/jats:italic>\n                    mutations to PD pathogenesis remain incompletely elucidated, and clinically validated early diagnostic biomarkers for\n                    <jats:italic>GBA1<\/jats:italic>\n                    -associated PD (\n                    <jats:italic>GBA1<\/jats:italic>\n                    -PD) are still lacking. This review summarizes the distinct clinical phenotypes and mechanistic underpinnings of\n                    <jats:italic>GBA1<\/jats:italic>\n                    -PD, with particular emphasis on omics-derived stratification biomarkers (identified through genomics, transcriptomics, proteomics, and lipidomics approaches) coupled with neuroimaging signatures. This review advances our understanding of\n                    <jats:italic>GBA1<\/jats:italic>\n                    -mediated PD pathogenesis while providing a framework for developing precision diagnostic strategies and targeted therapeutic interventions addressing PD heterogeneity.\n                  <\/jats:p>","DOI":"10.1186\/s13024-026-00931-7","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:17:51Z","timestamp":1769710671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multi-omics insights into GBA1-associated Parkinson\u2019s disease: interplay of genomics, transcriptomics, proteomics, and lipidomics"],"prefix":"10.1186","volume":"21","author":[{"given":"Yang","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"6","key":"931_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11910-024-01339-w","volume":"24","author":"JR Deliz","year":"2024","unstructured":"Deliz JR, Tanner CM, Gonzalez-Latapi P. Epidemiology of Parkinson\u2019s disease: an update. Curr Neurol Neurosci Rep. 2024;24(6):163\u201379.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"931_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner CM, Ostrem JL. Parkinson\u2019s disease. N Engl J Med. 2024;391(5):442\u201352.","journal-title":"N Engl J Med"},{"issue":"12","key":"931_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"10423","key":"931_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson\u2019s disease. Lancet. 2024;403(10423):283\u201392.","journal-title":"Lancet"},{"issue":"2","key":"931_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19(2):170\u20138.","journal-title":"Lancet Neurol"},{"issue":"17","key":"931_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"931_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s43587-024-00760-7","volume":"5","author":"EG Chew","year":"2025","unstructured":"Chew EG, Liu Z, Li Z, Chung SJ, Lian MM, Tandiono M, et al. Exome sequencing in Asian populations identifies low-frequency and rare coding variation influencing Parkinson\u2019s disease risk. Nat Aging. 2025;5(2):205\u201318.","journal-title":"Nat Aging"},{"issue":"9","key":"931_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41582-024-00999-z","volume":"20","author":"E Hertz","year":"2024","unstructured":"Hertz E, Chen Y, Sidransky E. Gaucher disease provides a unique window into Parkinson disease pathogenesis. Nat Reviews Neurol. 2024;20(9):526\u201340.","journal-title":"Nat Reviews Neurol"},{"key":"931_CR9","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/j.pharmthera.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Toffoli M, Schapira AHV. Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol Ther. 2023;246:108419.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"931_CR10","doi-asserted-by":"publisher","first-page":"e0167749","DOI":"10.1371\/journal.pone.0167749","volume":"11","author":"S Jes\u00fas","year":"2016","unstructured":"Jes\u00fas S, Huertas I, Bernal-Bernal I, Bonilla-Toribio M, C\u00e1ceres-Redondo MT, Vargas-Gonz\u00e1lez L, et al. GBA variants influence motor and Non-Motor features of parkinson\u2019s disease. PLoS One. 2016;11(12):e0167749.","journal-title":"PLoS One"},{"issue":"4","key":"931_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/ene.15230","volume":"29","author":"J Ren","year":"2022","unstructured":"Ren J, Zhang R, Pan C, Xu J, Sun H, Hua P, et al. Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort. Eur J Neurol. 2022;29(4):1017\u201324.","journal-title":"Eur J Neurol"},{"issue":"3","key":"931_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, et al. GBA-associated parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2015;30(3):407\u201311.","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, et al. Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener. 2021;10(1):4.","journal-title":"Transl Neurodegener"},{"key":"931_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.08.026","volume":"44","author":"LC Guedes","year":"2017","unstructured":"Guedes LC, Chan RB, Gomes MA, Concei\u00e7\u00e3o VA, Machado RB, Soares T, et al. Serum lipid alterations in GBA-associated parkinson\u2019s disease. Parkinsonism Relat Disord. 2017;44:58\u201365.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"931_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Cullen VC, Pereira DR, Yavuz Y, de Kam ML, Grievink HW, et al. A biomarker study in patients with GBA1-Parkinson\u2019s disease and healthy controls. Mov Disord. 2023;38(5):783\u201395.","journal-title":"Mov Disord"},{"issue":"3","key":"931_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4103\/1673-5374.202934","volume":"12","author":"KJ Kinghorn","year":"2017","unstructured":"Kinghorn KJ, Asghari AM, Castillo-Quan JI. The emerging role of autophagic-lysosomal dysfunction in gaucher disease and parkinson\u2019s disease. Neural Regeneration Res. 2017;12(3):380\u20134.","journal-title":"Neural Regeneration Res"},{"issue":"6","key":"931_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.26562","volume":"31","author":"T Moors","year":"2016","unstructured":"Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, et al. Lysosomal dysfunction and \u03b1-Synuclein aggregation in parkinson\u2019s disease: diagnostic links. Mov Disord. 2016;31(6):791\u2013801.","journal-title":"Mov Disord"},{"issue":"8","key":"931_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jpha.2023.06.011","volume":"13","author":"LM O\u2019Connor","year":"2023","unstructured":"O\u2019Connor LM, O\u2019Connor BA, Lim SB, Zeng J, Lo CH. Integrative multi-omics and systems bioinformatics in translational neuroscience: A data mining perspective. J Pharm Anal. 2023;13(8):836\u201350.","journal-title":"J Pharm Anal"},{"issue":"20","key":"931_CR19","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1073\/pnas.82.20.7101","volume":"82","author":"EI Ginns","year":"1985","unstructured":"Ginns EI, Choudary PV, Tsuji S, Martin B, Stubblefield B, Sawyer J, et al. Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for gaucher disease. Proc Natl Acad Sci USA. 1985;82(20):7101\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"931_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","volume":"4","author":"M Horowitz","year":"1989","unstructured":"Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 1989;4(1):87\u201396.","journal-title":"Genomics"},{"issue":"12","key":"931_CR21","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/mds.30006","volume":"39","author":"SRL Vieira","year":"2024","unstructured":"Vieira SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, Menozzi E, Mullin S, et al. Consensus guidance for genetic counseling in GBA1 variants: a focus on parkinson\u2019s disease. Mov Disord. 2024;39(12):2144\u201354.","journal-title":"Mov Disord"},{"issue":"9645","key":"931_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet"},{"issue":"2","key":"931_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of parkinson\u2019s disease in type 1 gaucher disease. J Inherit Metab Dis. 2010;33(2):167\u201373.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"931_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among gaucher disease carriers. J Med Genet. 2004;41(12):937\u201340.","journal-title":"J Med Genet"},{"issue":"19","key":"931_CR25","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa033277","volume":"351","author":"J Aharon-Peretz","year":"2004","unstructured":"Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med. 2004;351(19):1972\u20137.","journal-title":"N Engl J Med"},{"key":"931_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","volume":"11","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shu L, Sun Q, Zhou X, Pan H, Guo J, et al. Integrated genetic analysis of Racial differences of common GBA variants in parkinson\u2019s disease: A Meta-Analysis. Front Mol Neurosci. 2018;11:43.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"931_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.29314","volume":"38","author":"SC Parlar","year":"2023","unstructured":"Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 variants in parkinson\u2019s disease: the GBA1-PD browser. Mov Disord. 2023;38(3):489\u201395.","journal-title":"Mov Disord"},{"issue":"12","key":"931_CR28","doi-asserted-by":"publisher","first-page":"e115747","DOI":"10.1371\/journal.pone.0115747","volume":"9","author":"J Chen","year":"2014","unstructured":"Chen J, Li W, Zhang T, Wang YJ, Jiang XJ, Xu ZQ. Glucocerebrosidase gene mutations associated with parkinson\u2019s disease: a meta-analysis in a Chinese population. PLoS One. 2014;9(12):e115747.","journal-title":"PLoS One"},{"issue":"8","key":"931_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/mds.23009","volume":"25","author":"QY Sun","year":"2010","unstructured":"Sun QY, Guo JF, Wang L, Yu RH, Zuo X, Yao LY, et al. Glucocerebrosidase gene L444P mutation is a risk factor for parkinson\u2019s disease in Chinese population. Mov Disord. 2010;25(8):1005\u201311.","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41531-023-00571-4","volume":"9","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang Y, Wan J, Zhao Y, Pan H, Zeng Q, et al. Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):129.","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"931_CR31","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/mds.28200","volume":"35","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in parkinson\u2019s disease: a kin cohort study. Mov Disord. 2020;35(11):2111\u20134.","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012;78(6):417\u201320.","journal-title":"Neurology"},{"issue":"4","key":"931_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1212\/01.wnl.0000327823.81237.d1","volume":"72","author":"WC Nichols","year":"2009","unstructured":"Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with Familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72(4):310\u20136.","journal-title":"Neurology"},{"issue":"3","key":"931_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.22687","volume":"71","author":"N Pankratz","year":"2012","unstructured":"Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, et al. Meta-analysis of parkinson\u2019s disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370\u201384.","journal-title":"Ann Neurol"},{"issue":"9","key":"931_CR35","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84(9):880\u20137.","journal-title":"Neurology"},{"issue":"12","key":"931_CR36","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1093\/brain\/awae222","volume":"147","author":"SH Kweon","year":"2024","unstructured":"Kweon SH, Ryu HG, Kwon SH, Park H, Lee S, Kim NS, et al. Gba1 E326K renders motor and non-motor symptoms with pathological \u03b1-synuclein, Tau and glial activation. Brain. 2024;147(12):4072\u201383.","journal-title":"Brain"},{"issue":"1","key":"931_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.26359","volume":"31","author":"IF Mata","year":"2016","unstructured":"Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, et al. GBA variants are associated with a distinct pattern of cognitive deficits in parkinson\u2019s disease. Mov Disord. 2016;31(1):95\u2013102.","journal-title":"Mov Disord"},{"issue":"7","key":"931_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1001\/jamaneurol.2013.1274","volume":"70","author":"LM Chahine","year":"2013","unstructured":"Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70(7):852\u20138.","journal-title":"JAMA Neurol"},{"issue":"11","key":"931_CR39","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/mds.28195","volume":"35","author":"S Petrucci","year":"2020","unstructured":"Petrucci S, Ginevrino M, Trezzi I, Monfrini E, Ricciardi L, Albanese A, et al. GBA-Related parkinson\u2019s disease: dissection of Genotype-Phenotype correlates in a large Italian cohort. Mov Disord. 2020;35(11):2106\u201311.","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR40","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752\u20137.","journal-title":"JAMA Neurol"},{"issue":"1","key":"931_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, et al. Genetic modifiers of risk and age at onset in GBA associated parkinson\u2019s disease and lewy body dementia. Brain. 2020;143(1):234\u201348.","journal-title":"Brain"},{"issue":"4","key":"931_CR42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mds.29348","volume":"38","author":"A Thaler","year":"2023","unstructured":"Thaler A, Mirelman A, Alcalay RN. Differences in Sex-Specific frequency of glucocerebrosidase variant carriers and Familial parkinsonism. Mov Disord. 2023;38(4):713\u20134.","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR43","doi-asserted-by":"publisher","first-page":"e14387","DOI":"10.1111\/cns.14387","volume":"30","author":"J Ren","year":"2024","unstructured":"Ren J, Zhan X, Zhou H, Guo Z, Xing Y, Yin H, et al. Comparing the effects of GBA variants and onset age on clinical features and progression in parkinson\u2019s disease. CNS Neurosci Ther. 2024;30(2):e14387.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"931_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, et al. Impact of GBA1 variants on long-term clinical progression and mortality in incident parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;91(7):695\u2013702.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"931_CR45","doi-asserted-by":"publisher","first-page":"725.e1","DOI":"10.1016\/j.neurobiolaging.2013.08.012","volume":"35","author":"C Wang","year":"2014","unstructured":"Wang C, Cai Y, Gu Z, Ma J, Zheng Z, Tang BS, et al. Clinical profiles of parkinson\u2019s disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiol Aging. 2014;35(3):725.e1\u20136.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"931_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-022-00294-1","volume":"11","author":"J Huang","year":"2022","unstructured":"Huang J, Cheng Y, Li C, Shang H. Genetic heterogeneity on sleep disorders in parkinson\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener. 2022;11(1):21.","journal-title":"Transl Neurodegener"},{"issue":"9","key":"931_CR47","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/mds.27775","volume":"34","author":"S Mullin","year":"2019","unstructured":"Mullin S, Beavan M, Bestwick J, McNeill A, Proukakis C, Cox T, et al. Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. Mov Disord. 2019;34(9):1365\u201373.","journal-title":"Mov Disord"},{"key":"931_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","volume":"55","author":"A Thaler","year":"2018","unstructured":"Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, et al. Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord. 2018;55:45\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"931_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/mds.24045","volume":"27","author":"N Set\u00f3-Salvia","year":"2012","unstructured":"Set\u00f3-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, et al. Glucocerebrosidase mutations confer a greater risk of dementia during parkinson\u2019s disease course. Mov Disord. 2012;27(3):393\u20139.","journal-title":"Mov Disord"},{"key":"931_CR50","doi-asserted-by":"publisher","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","volume":"141","author":"S Gaubert","year":"2022","unstructured":"Gaubert S, Hourregue C, Mouton-Liger F, Millot P, Franco M, Amar-Bouaziz E, et al. Exploring the link between GBA1 mutations and dementia with lewy bodies, A mini-review. Neurosci Biobehav Rev. 2022;141:104856.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"931_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol. 2013;70(6):727\u201335.","journal-title":"JAMA Neurol"},{"issue":"1","key":"931_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ana.26636","volume":"94","author":"A Lanore","year":"2023","unstructured":"Lanore A, Casse F, Tesson C, Courtin T, Menon PJ, Sambin S, et al. Differences in survival across Monogenic forms of parkinson\u2019s disease. Ann Neurol. 2023;94(1):123\u201332.","journal-title":"Ann Neurol"},{"issue":"5","key":"931_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S, et al. Survival and dementia in GBA-associated parkinson\u2019s disease: the mutation matters. Ann Neurol. 2016;80(5):662\u201373.","journal-title":"Ann Neurol"},{"issue":"4","key":"931_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3233\/JPD-171172","volume":"7","author":"V Lythe","year":"2017","unstructured":"Lythe V, Athauda D, Foley J, Mencacci NE, Jahanshahi M, Cipolotti L, et al. GBA-Associated parkinson\u2019s disease: progression in a deep brain stimulation cohort. J Parkinson\u2019s Disease. 2017;7(4):635\u201344.","journal-title":"J Parkinson\u2019s Disease"},{"issue":"3","key":"931_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.26302","volume":"91","author":"G Pal","year":"2022","unstructured":"Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, et al. Parkinson disease and subthalamic nucleus deep brain stimulation: cognitive effects in GBA mutation carriers. Ann Neurol. 2022;91(3):424\u201335.","journal-title":"Ann Neurol"},{"issue":"4","key":"931_CR56","first-page":"309","volume":"95","author":"M Avenali","year":"2024","unstructured":"Avenali M, Zangaglia R, Cuconato G, Palmieri I, Albanese A, Artusi CA, et al. Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry. 2024;95(4):309\u201315.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"931_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wu H, Tang B, Guo J. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated parkinson\u2019s disease. Transl Neurodegener. 2024;13(1):48.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"931_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"issue":"3","key":"931_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1523\/JNEUROSCI.0680-22.2022","volume":"43","author":"CL Mahoney-Crane","year":"2023","unstructured":"Mahoney-Crane CL, Viswanathan M, Russell D, Curtiss RAC, Freire J, Bobba SS, et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal Alpha-Synuclein inclusions. J Neurosci. 2023;43(3):501\u201321.","journal-title":"J Neurosci"},{"issue":"5","key":"931_CR60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","volume":"120","author":"O Goker-Alpan","year":"2010","unstructured":"Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in \u03b1-synuclein inclusions in lewy body disorders. Acta Neuropathol. 2010;120(5):641\u20139.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"931_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","volume":"46","author":"B Rosenbloom","year":"2011","unstructured":"Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, et al. The incidence of parkinsonism in patients with type 1 gaucher disease: data from the ICGG gaucher registry. Blood Cells Mol Dis. 2011;46(1):95\u2013102.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"931_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14(1):36.","journal-title":"Mol Neurodegener"},{"key":"931_CR63","doi-asserted-by":"crossref","unstructured":"Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G, et al. GBA1-associated Parkinson\u2019s disease is a distinct entity. Int J Mol Sci. 2024;25(13):7102.","DOI":"10.3390\/ijms25137102"},{"issue":"6","key":"931_CR64","doi-asserted-by":"publisher","first-page":"eabm6393","DOI":"10.1126\/sciadv.abm6393","volume":"8","author":"SH Kuo","year":"2022","unstructured":"Kuo SH, Tasset I, Cheng MM, Diaz A, Pan MK, Lieberman OJ, et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by Blockade of chaperone-mediated autophagy. Sci Adv. 2022;8(6):eabm6393.","journal-title":"Sci Adv"},{"issue":"1","key":"931_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-022-00554-8","volume":"17","author":"GM Riboldi","year":"2022","unstructured":"Riboldi GM, Vialle RA, Navarro E, Udine E, de Paiva Lopes K, Humphrey J, et al. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related parkinson\u2019s disease. Mol Neurodegener. 2022;17(1):52.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"931_CR66","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden P, Perez MJ, Raji H, Bertoli F, Kalb S, Illescas M, et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun. 2023;14(1):1930.","journal-title":"Nat Commun"},{"issue":"1","key":"931_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, et al. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy. 2019;15(1):113\u201330.","journal-title":"Autophagy"},{"issue":"8","key":"931_CR68","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11(8):1261.","journal-title":"Cells"},{"issue":"13","key":"931_CR69","doi-asserted-by":"publisher","first-page":"e188413","DOI":"10.1172\/jci.insight.188413","volume":"10","author":"S Nuber","year":"2025","unstructured":"Nuber S, Hsiang H, Keewan E, Moors TE, Reitz SJ, Tiwari A, et al. Stearoyl-CoA desaturase Inhibition normalizes brain lipid saturation, \u03b1-synuclein homeostasis, and motor function in mutant Gba1-Parkinson mice. JCI Insight. 2025;10(13):e188413.","journal-title":"JCI Insight"},{"issue":"3","key":"931_CR70","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00415-021-10713-4","volume":"269","author":"M Leocadi","year":"2022","unstructured":"Leocadi M, Canu E, Donzuso G, Stojkovic T, Basaia S, Kresojevi\u0107 N, et al. Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive parkinson\u2019s disease patients. J Neurol. 2022;269(3):1485\u2013500.","journal-title":"J Neurol"},{"issue":"10","key":"931_CR71","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1007\/s00415-022-11181-0","volume":"269","author":"S Ghatti","year":"2022","unstructured":"Ghatti S, Yoon E, Lopez G, Ehrlich D, Horovitz SG. Imaging and genetics in parkinson\u2019s disease: assessment of the GBA1 mutation. J Neurol. 2022;269(10):5347\u201355.","journal-title":"J Neurol"},{"issue":"11","key":"931_CR72","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/mds.29578","volume":"38","author":"C Andica","year":"2023","unstructured":"Andica C, Kamagata K, Uchida W, Saito Y, Takabayashi K, Hagiwara A, et al. Fiber-Specific white matter alterations in parkinson\u2019s disease patients with GBA gene mutations. Mov Disord. 2023;38(11):2019\u201330.","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mds.25397","volume":"28","author":"F Agosta","year":"2013","unstructured":"Agosta F, Kostic VS, Davidovic K, Kresojevi\u0107 N, Sarro L, Svetel M, et al. White matter abnormalities in parkinson\u2019s disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013;28(6):772\u20138.","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR74","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00234-022-03067-9","volume":"65","author":"Y Hou","year":"2023","unstructured":"Hou Y, Feng F, Zhang L, Ou R, Lin J, Gong Q, et al. Disrupted topological organization of resting-state functional brain networks in parkinson\u2019s disease patients with glucocerebrosidase gene mutations. Neuroradiology. 2023;65(2):361\u201370.","journal-title":"Neuroradiology"},{"issue":"12","key":"931_CR75","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/mds.28225","volume":"35","author":"A Greuel","year":"2020","unstructured":"Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, J\u00e4ger C, et al. GBA variants in parkinson\u2019s disease: Clinical, Metabolomic, and multimodal neuroimaging phenotypes. Mov Disord. 2020;35(12):2201\u201310.","journal-title":"Mov Disord"},{"issue":"7","key":"931_CR76","doi-asserted-by":"publisher","first-page":"e3060","DOI":"10.1002\/brb3.3060","volume":"13","author":"S Grisanti","year":"2023","unstructured":"Grisanti S, Fraternali A, Cavallieri F, Fioravanti V, Casali M, Toschi G, et al. Quantitative dopamine transporter imaging assessment in parkinson\u2019s disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study. Brain Behav. 2023;13(7):e3060.","journal-title":"Brain Behav"},{"issue":"1","key":"931_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mds.28818","volume":"37","author":"SP Caminiti","year":"2022","unstructured":"Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and dopamine transporter imaging trajectories in a cohort of parkinson\u2019s disease patients with GBA mutations. Mov Disord. 2022;37(1):106\u201318.","journal-title":"Mov Disord"},{"issue":"2","key":"931_CR78","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/ene.15615","volume":"30","author":"MS Kim","year":"2023","unstructured":"Kim MS, Park DG, An YS, Yoon JH. Dual-phase (18) F-FP-CIT positron emission tomography and cardiac (123) I-MIBG scintigraphy of parkinson\u2019s disease patients with GBA mutations: evidence of the body-first type? Eur J Neurol. 2023;30(2):344\u201352.","journal-title":"Eur J Neurol"},{"issue":"3","key":"931_CR79","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/brain\/awad323","volume":"147","author":"S Slingerland","year":"2024","unstructured":"Slingerland S, van der Zee S, Carli G, Slomp AC, Boertien JM, d\u2019Angremont E, et al. Cholinergic innervation topography in GBA-associated de Novo parkinson\u2019s disease patients. Brain. 2024;147(3):900\u201310.","journal-title":"Brain"},{"issue":"1","key":"931_CR80","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41531-023-00616-8","volume":"9","author":"I Rosety","year":"2023","unstructured":"Rosety I, Zagare A, Saraiva C, Nickels S, Antony P, Almeida C, et al. Impaired neuron differentiation in GBA-associated parkinson\u2019s disease is linked to cell cycle defects in organoids. NPJ Parkinsons Dis. 2023;9(1):166.","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"931_CR81","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/genes12101545","volume":"12","author":"T Usenko","year":"2021","unstructured":"Usenko T, Bezrukova A, Basharova K, Panteleeva A, Nikolaev M, Kopytova A, et al. Comparative transcriptome analysis in Monocyte-Derived macrophages of asymptomatic GBA mutation carriers and patients with GBA-Associated parkinson\u2019s disease. Genes. 2021;12(10):1545.","journal-title":"Genes"},{"issue":"1","key":"931_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41531-024-00653-x","volume":"10","author":"I Rosh","year":"2024","unstructured":"Rosh I, Tripathi U, Hussein Y, Rike WA, Djamus J, Shklyar B, et al. Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 parkinson\u2019s disease patients. NPJ Parkinsons Dis. 2024;10(1):38.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"931_CR83","doi-asserted-by":"publisher","first-page":"8484","DOI":"10.1038\/s41467-025-63444-9","volume":"16","author":"DJ Vidyadhara","year":"2025","unstructured":"Vidyadhara DJ, B\u00e4ckstr\u00f6m D, Chakraborty R, Ruan J, Park JM, Mistry PK, et al. Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked parkinson\u2019s disease and dementia with lewy bodies. Nat Commun. 2025;16(1):8484.","journal-title":"Nat Commun"},{"issue":"Pt 9","key":"931_CR84","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, et al. Glucocerebrosidase activity in parkinson\u2019s disease with and without GBA mutations. Brain. 2015;138(Pt 9):2648\u201358.","journal-title":"Brain"},{"issue":"5","key":"931_CR85","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche S, Schulte C, Wurster I, Machetanz G, Roeben B, Zimmermann M, et al. The mutation matters: CSF profiles of GCase, Sphingolipids, \u03b1-Synuclein in PD(GBA). Mov Disord. 2021;36(5):1216\u201328.","journal-title":"Mov Disord"},{"issue":"4","key":"931_CR86","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","volume":"100","author":"L Oftedal","year":"2023","unstructured":"Oftedal L, Maple-Gr\u00f8dem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, et al. Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease. Neurology. 2023;100(4):e388\u201395.","journal-title":"Neurology"},{"issue":"10","key":"931_CR87","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, et al. Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients. Mov Disord. 2017;32(10):1423\u201331.","journal-title":"Mov Disord"},{"issue":"6","key":"931_CR88","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1212\/WNL.0000000000009989","volume":"95","author":"YE Huh","year":"2020","unstructured":"Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, et al. \u03b2-Glucocerebrosidase activity in GBA-linked Parkinson disease: the type of mutation matters. Neurology. 2020;95(6):e685\u201396.","journal-title":"Neurology"},{"issue":"3","key":"931_CR89","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia Nigra of Parkinson disease brains. Ann Neurol. 2012;72(3):455\u201363.","journal-title":"Ann Neurol"},{"issue":"1","key":"931_CR90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41531-024-00645-x","volume":"10","author":"S Blumenreich","year":"2024","unstructured":"Blumenreich S, Nehushtan T, Kupervaser M, Shalit T, Gabashvili A, Joseph T, et al. Large-scale proteomics analysis of five brain regions from parkinson\u2019s disease patients with a GBA1 mutation. NPJ Parkinsons Dis. 2024;10(1):33.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"931_CR91","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","volume":"17","author":"A Dardis","year":"2022","unstructured":"Dardis A, Michelakakis H, Rozenfeld P, Fumic K, Wagner J, Pavan E, et al. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet J Rare Dis. 2022;17(1):442.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"931_CR92","doi-asserted-by":"publisher","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, et al. Reduced glucocerebrosidase activity in monocytes from patients with parkinson\u2019s disease. Sci Rep. 2018;8(1):15446.","journal-title":"Sci Rep"},{"issue":"1","key":"931_CR93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns CEG, Prigent A, Beezhold B, Yao L, Hatcher NG, Tao P, et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):74.","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"931_CR94","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ymgme.2011.04.015","volume":"103","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen L, Neumann J, O\u2019Sullivan SS, Holton JL, Revesz T, Hardy J, et al. Glucocerebrosidase mutations do not cause increased lewy body pathology in parkinson\u2019s disease. Mol Genet Metab. 2011;103(4):410\u20132.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"931_CR95","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/mds.28496","volume":"36","author":"M Avenali","year":"2021","unstructured":"Avenali M, Cerri S, Ongari G, Ghezzi C, Pacchetti C, Tassorelli C, et al. Profiling the biochemical signature of GBA-Related parkinson\u2019s disease in peripheral blood mononuclear cells. Mov Disord. 2021;36(5):1267\u201372.","journal-title":"Mov Disord"},{"key":"931_CR96","doi-asserted-by":"publisher","first-page":"107321","DOI":"10.1016\/j.parkreldis.2025.107321","volume":"133","author":"K Dimoula","year":"2025","unstructured":"Dimoula K, Papagiannakis N, Maniati M, Stefanis L, Emmanouilidou E. Aggregated \u03b1-synuclein in erythrocytes as a potential biomarker for idiopathic parkinson\u2019s disease. Parkinsonism Relat Disord. 2025;133:107321.","journal-title":"Parkinsonism Relat Disord"},{"key":"931_CR97","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","volume":"636","author":"S Pchelina","year":"2017","unstructured":"Pchelina S, Emelyanov A, Baydakova G, Andoskin P, Senkevich K, Nikolaev M, et al. Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated parkinson\u2019s disease. Neurosci Lett. 2017;636:70\u20136.","journal-title":"Neurosci Lett"},{"issue":"6478","key":"931_CR98","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Sci. 2020;367(6478):eaau6977.","journal-title":"Science"},{"issue":"2","key":"931_CR99","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/ijms25021136","volume":"25","author":"A Gualerzi","year":"2024","unstructured":"Gualerzi A, Picciolini S, Bedoni M, Guerini FR, Clerici M, Agliardi C. Extracellular vesicles as biomarkers for parkinson\u2019s disease: how Far from clinical translation? Int J Mol Sci. 2024;25(2):1136.","journal-title":"Int J Mol Sci"},{"key":"931_CR100","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"931_CR101","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3390\/ijms22042215","volume":"22","author":"S Cerri","year":"2021","unstructured":"Cerri S, Ghezzi C, Ongari G, Croce S, Avenali M, Zangaglia R, et al. GBA mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson\u2019s disease. Int J Mol Sci. 2021;22(4):2215.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"931_CR102","first-page":"1696","volume":"27","author":"VE Papadopoulos","year":"2018","unstructured":"Papadopoulos VE, Nikolopoulou G, Antoniadou I, Karachaliou A, Arianoglou G, Emmanouilidou E, et al. Modulation of \u03b2-glucocerebrosidase increases \u03b1-synuclein secretion and exosome release in mouse models of parkinson\u2019s disease. Hum Mol Genet. 2018;27(10):1696\u2013710.","journal-title":"Hum Mol Genet"},{"key":"931_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2021.06.033","volume":"469","author":"H Zheng","year":"2021","unstructured":"Zheng H, Xie Z, Zhang X, Mao J, Wang M, Wei S, et al. Investigation of \u03b1-Synuclein species in plasma exosomes and the oligomeric and phosphorylated \u03b1-Synuclein as potential peripheral biomarker of parkinson\u2019s disease. Neuroscience. 2021;469:79\u201390.","journal-title":"Neuroscience"},{"issue":"6","key":"931_CR104","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","volume":"27","author":"M Niu","year":"2020","unstructured":"Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, et al. A longitudinal study on \u03b1-synuclein in plasma neuronal exosomes as a biomarker for parkinson\u2019s disease development and progression. Eur J Neurol. 2020;27(6):967\u201374.","journal-title":"Eur J Neurol"},{"issue":"1","key":"931_CR105","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41531-023-00457-5","volume":"9","author":"L Mu\u00f1oz-Delgado","year":"2023","unstructured":"Mu\u00f1oz-Delgado L, Mac\u00edas-Garc\u00eda D, Peri\u00f1\u00e1n MT, Jes\u00fas S, Adarmes-G\u00f3mez AD, Bonilla Toribio M, et al. Peripheral inflammatory immune response differs among sporadic and Familial parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):12.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"931_CR106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41531-023-00476-2","volume":"9","author":"S Lerche","year":"2023","unstructured":"Lerche S, Zimmermann M, Roeben B, Wurster I, Fries FL, Deuschle C, et al. Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD. NPJ Parkinsons Dis. 2023;9(1):38.","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"931_CR107","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s41374-022-00830-7","volume":"102","author":"M Cui","year":"2022","unstructured":"Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest. 2022;102(11):1170\u201381.","journal-title":"Lab Invest"},{"issue":"3","key":"931_CR108","doi-asserted-by":"publisher","first-page":"112180","DOI":"10.1016\/j.celrep.2023.112180","volume":"42","author":"H Bogetofte","year":"2023","unstructured":"Bogetofte H, Ryan BJ, Jensen P, Schmidt SI, Vergoossen DLE, Barnkob MB, et al. Post-translational proteomics platform identifies neurite outgrowth impairments in parkinson\u2019s disease GBA-N370S dopamine neurons. Cell Rep. 2023;42(3):112180.","journal-title":"Cell Rep"},{"issue":"22","key":"931_CR109","doi-asserted-by":"publisher","first-page":"14166","DOI":"10.3390\/ijms232214166","volume":"23","author":"S Zafar","year":"2022","unstructured":"Zafar S, Noor A, Younas N, Shafiq M, Schmitz M, Wurster I, et al. SWATH mass Spectrometry-Based CSF proteome profile of GBA-Linked parkinson\u2019s disease patients. Int J Mol Sci. 2022;23(22):14166.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"931_CR110","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/ijms25010683","volume":"25","author":"R Kojima","year":"2024","unstructured":"Kojima R, Paslawski W, Lyu G, Arenas E, Zhang X, Svenningsson P. Secretome analyses identify FKBP4 as a GBA1-Associated protein in CSF and iPS cells from parkinson\u2019s disease patients with GBA1 mutations. Int J Mol Sci. 2024;25(1):683.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"931_CR111","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper J, Dean NJ, Pickford R, Lewis SJG, Halliday GM, Kim WS, et al. Lipid pathway dysfunction is prevalent in patients with parkinson\u2019s disease. Brain. 2022;145(10):3472\u201387.","journal-title":"Brain"},{"key":"931_CR112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL G\u00fcndner","year":"2019","unstructured":"G\u00fcndner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, et al. Path mediation analysis reveals GBA impacts lewy body disease status by increasing \u03b1-synuclein levels. Neurobiol Dis. 2019;121:205\u201313.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"931_CR113","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich S, Nehushtan T, Barav OB, Saville JT, Dingjan T, Hardy J, et al. Elevation of gangliosides in four brain regions from parkinson\u2019s disease patients with a GBA mutation. NPJ Parkinsons Dis. 2022;8(1):99.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"931_CR114","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41531-024-00820-0","volume":"10","author":"S Lerche","year":"2024","unstructured":"Lerche S, Wurster I, Valente EM, Avenali M, Samaniego D, Mart\u00ednez-Vicente M, et al. CSF d18:1 sphingolipid species in Parkinson disease and dementia with lewy bodies with and without GBA1 variants. NPJ Parkinsons Dis. 2024;10(1):198.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"931_CR115","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mds.28846","volume":"37","author":"M Surface","year":"2022","unstructured":"Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, et al. Plasma glucosylsphingosine in GBA1 mutation carriers with and without parkinson\u2019s disease. Mov Disord. 2022;37(2):416\u201321.","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR116","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of \u03b1-Synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97(1):92\u2013107.e10.","journal-title":"Neuron"},{"issue":"3","key":"931_CR117","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/brain\/awab371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion C, Marlet FR, Cerri S, Schapira AHV, Blandini F, Di Monte DA. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain. 2022;145(3):1038\u201351.","journal-title":"Brain"},{"issue":"35","key":"931_CR118","doi-asserted-by":"publisher","first-page":"12459","DOI":"10.1073\/pnas.0500893102","volume":"102","author":"R Jennemann","year":"2005","unstructured":"Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, et al. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci USA. 2005;102(35):12459\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"931_CR119","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5650\/jos.60.537","volume":"60","author":"RK Yu","year":"2011","unstructured":"Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides\u2013an overview. J Oleo Sci. 2011;60(10):537\u201344.","journal-title":"J Oleo Sci"},{"issue":"10","key":"931_CR120","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1021\/cr2002917","volume":"111","author":"AH Merrill","year":"2011","unstructured":"Merrill AH. Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev. 2011;111(10):6387\u2013422.","journal-title":"Chem Rev"},{"issue":"31","key":"931_CR121","doi-asserted-by":"publisher","first-page":"12875","DOI":"10.1021\/acs.analchem.4c02654","volume":"96","author":"L Castillo-Ribelles","year":"2024","unstructured":"Castillo-Ribelles L, Arranz-Amo JA, Hern\u00e1ndez-Vara J, Samaniego-Toro D, Enriquez-Calzada S, Pozo SL, et al. Evaluation of a liquid Chromatography-Tandem mass spectrometry method for the analysis of glucosylceramide and Galactosylceramide isoforms in cerebrospinal fluid of parkinson\u2019s disease patients. Anal Chem. 2024;96(31):12875\u201382.","journal-title":"Anal Chem"},{"issue":"11","key":"931_CR122","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","volume":"27","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Jeon S, Burbulla LF, Krainc D. Acid ceramidase Inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet. 2018;27(11):1972\u201388.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"931_CR123","doi-asserted-by":"publisher","first-page":"e73094","DOI":"10.1371\/journal.pone.0073094","volume":"8","author":"MM Mielke","year":"2013","unstructured":"Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R, Deuschle C, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic parkinson\u2019s disease and associated with cognitive impairment: a pilot study. PLoS One. 2013;8(9):e73094.","journal-title":"PLoS One"},{"issue":"3","key":"931_CR124","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41556-024-01364-4","volume":"26","author":"AJ Mathiowetz","year":"2024","unstructured":"Mathiowetz AJ, Olzmann JA. Lipid droplets and cellular lipid flux. Nat Cell Biol. 2024;26(3):331\u201345.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"931_CR125","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41419-020-03254-7","volume":"12","author":"NP Alza","year":"2021","unstructured":"Alza NP, Conde MA, Scodelaro-Bilbao PG, Salvador GA. Neutral lipids as early biomarkers of cellular fate: the case of \u03b1-synuclein overexpression. Cell Death Dis. 2021;12(1):52.","journal-title":"Cell Death Dis"},{"issue":"5","key":"931_CR126","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","volume":"73","author":"S Fanning","year":"2019","unstructured":"Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, et al. Lipidomic analysis of \u03b1-Synuclein neurotoxicity identifies Stearoyl coa desaturase as a target for Parkinson treatment. Mol Cell. 2019;73(5):1001\u201314.e8.","journal-title":"Mol Cell"},{"issue":"5","key":"931_CR127","first-page":"773","volume":"32","author":"LJ Smith","year":"2023","unstructured":"Smith LJ, Bolsinger MM, Chau KY, Gegg ME, Schapira AHV. The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Hum Mol Genet. 2023;32(5):773\u201389.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"931_CR128","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jnc.15136","volume":"156","author":"S Blumenreich","year":"2021","unstructured":"Blumenreich S, Yaacobi C, Vardi A, Barav OB, Vitner EB, Park H, et al. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of gaucher disease. J Neurochem. 2021;156(5):692\u2013701.","journal-title":"J Neurochem"},{"issue":"16","key":"931_CR129","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AH. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25(16):3432\u201345.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"931_CR130","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.27119","volume":"32","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodr\u00edguez-Traver E, Kulisevsky J, et al. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in parkinson\u2019s disease. Mov Disord. 2017;32(10):1409\u201322.","journal-title":"Mov Disord"},{"issue":"5","key":"931_CR131","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/mds.28396","volume":"36","author":"P Garc\u00eda-Sanz","year":"2021","unstructured":"Garc\u00eda-Sanz P, M F G Aerts J, Moratalla R. The role of cholesterol in \u03b1-Synuclein and lewy body pathology in GBA1 parkinson\u2019s disease. Mov Disord. 2021;36(5):1070\u201385.","journal-title":"Mov Disord"},{"issue":"8","key":"931_CR132","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AH. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord. 2015;30(8):1085\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"931_CR133","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41531-021-00206-6","volume":"7","author":"D Mac\u00edas-Garc\u00eda","year":"2021","unstructured":"Mac\u00edas-Garc\u00eda D, Peri\u00f1\u00e1n MT, Mu\u00f1oz-Delgado L, Jimenez-Jaraba MV, Labrador-Espinosa M, Jes\u00fas S, et al. Serum lipid profile among sporadic and Familial forms of parkinson\u2019s disease. NPJ Parkinsons Dis. 2021;7(1):59.","journal-title":"NPJ Parkinsons Dis"},{"key":"931_CR134","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fncel.2018.00125","volume":"12","author":"S Cerri","year":"2018","unstructured":"Cerri S, Ghezzi C, Sampieri M, Siani F, Avenali M, Dornini G, et al. The Exosomal\/Total \u03b1-Synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients. Front Cell Neurosci. 2018;12:125.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"931_CR135","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh YE, Park H, Chiang MSR, Tuncali I, Liu G, Locascio JJ, et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic parkinson\u2019s disease enrolled in PPMI. NPJ Parkinsons Dis. 2021;7(1):102.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"931_CR136","doi-asserted-by":"publisher","first-page":"82","DOI":"10.13078\/jsm.250016","volume":"22","author":"A Wise","year":"2025","unstructured":"Wise A, Raymond D, Yang M, Astefanous A, Cohen A, Beltre M, et al. More than rapid eye movement sleep behavior disorder: sleep differences in parkinson\u2019s disease LRRK2 and GBA genotypes. J Sleep Med. 2025;22(2):82\u201390.","journal-title":"J Sleep Med"},{"issue":"5","key":"931_CR137","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407\u201317.","journal-title":"Lancet Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-026-00931-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:21:46Z","timestamp":1781630506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-026-00931-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1186\/s13024-026-00931-7","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}